- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 16th, 2007
By Jack Uldrich August 16, 2007
While reading an interesting article about the link between academic research and commercial products, I stumbled upon an intriguing company experimenting with a novel -- and tiny -- new way to fight cancer.
Insert Therapeutics, a subsidiary of Arrowhead Research (Nasdaq: ARWR), specializes in developing promising nanotechnology-related university research. It seems that Insert Therapeutics is focusing on an innovative new nanotech-based platform for the treatment of cancer, and it's helping to shepherd the platform through the FDA clinical phase process. The drug in question is only in phase 1 of FDA trials, so it still has a long way to go, and there's absolutely no guarantee that it will ever receive final approval.
|Related News Press|
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Graphenea embarks on a new era April 16th, 2015
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
New technique for exploring structural dynamics of nanoworld: Developed in a Nobel laureate's laboratory at Caltech, hybrid approach allows ultrafast EM analysis of materials, showing tiny electronic changes in individual atoms within a material on ultrafast time scales April 28th, 2015